PE20171338A1 - Compuestos y composiciones como inhibidores de quinasa raf - Google Patents
Compuestos y composiciones como inhibidores de quinasa rafInfo
- Publication number
- PE20171338A1 PE20171338A1 PE2017000445A PE2017000445A PE20171338A1 PE 20171338 A1 PE20171338 A1 PE 20171338A1 PE 2017000445 A PE2017000445 A PE 2017000445A PE 2017000445 A PE2017000445 A PE 2017000445A PE 20171338 A1 PE20171338 A1 PE 20171338A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- compositions
- phenyl
- methyl
- kinase inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000009929 raf Kinases Human genes 0.000 title abstract 2
- 108010077182 raf Kinases Proteins 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- -1 2 - ((4- (2-methyl-5- (2- (trifluoromethyl) isonicotinamido) phenyl) -6-morpholinopyridin-2-yl) oxy) ethyl Chemical group 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049469P | 2014-09-12 | 2014-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171338A1 true PE20171338A1 (es) | 2017-09-13 |
Family
ID=54148595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000445A PE20171338A1 (es) | 2014-09-12 | 2015-09-11 | Compuestos y composiciones como inhibidores de quinasa raf |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9573969B2 (OSRAM) |
| EP (1) | EP3191472B1 (OSRAM) |
| JP (1) | JP6678655B2 (OSRAM) |
| KR (1) | KR20170053686A (OSRAM) |
| CN (1) | CN107108671B (OSRAM) |
| AP (1) | AP2017009830A0 (OSRAM) |
| AR (1) | AR101815A1 (OSRAM) |
| AU (1) | AU2015313782B2 (OSRAM) |
| BR (1) | BR112017004741A2 (OSRAM) |
| CA (1) | CA2960971A1 (OSRAM) |
| CL (1) | CL2017000541A1 (OSRAM) |
| CO (1) | CO2017002292A2 (OSRAM) |
| CR (1) | CR20170092A (OSRAM) |
| CU (1) | CU20170026A7 (OSRAM) |
| DO (1) | DOP2017000066A (OSRAM) |
| EA (1) | EA031061B1 (OSRAM) |
| EC (1) | ECSP17021897A (OSRAM) |
| ES (1) | ES2729243T3 (OSRAM) |
| IL (1) | IL250950A0 (OSRAM) |
| MX (1) | MX2017003233A (OSRAM) |
| NI (1) | NI201700029A (OSRAM) |
| PE (1) | PE20171338A1 (OSRAM) |
| PH (1) | PH12017500416A1 (OSRAM) |
| SG (1) | SG11201701734QA (OSRAM) |
| SV (1) | SV2017005405A (OSRAM) |
| TN (1) | TN2017000075A1 (OSRAM) |
| TW (1) | TWI603977B (OSRAM) |
| UY (1) | UY36294A (OSRAM) |
| WO (1) | WO2016038581A1 (OSRAM) |
| ZA (1) | ZA201701633B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014140075A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| MY182908A (en) * | 2014-01-14 | 2021-02-05 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| JP2017526716A (ja) | 2014-09-12 | 2017-09-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃのスピロ環状阻害剤 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| AU2017329090B9 (en) * | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| MX393855B (es) | 2017-05-02 | 2025-03-21 | Novartis Ag | Terapia de combinación que comprende un inhibidor de raf y trametinib |
| EP3661516A1 (en) * | 2017-08-03 | 2020-06-10 | Novartis AG | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
| AU2020244761A1 (en) * | 2019-03-22 | 2021-11-11 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| US10927111B2 (en) | 2019-05-03 | 2021-02-23 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| AU2020276695B2 (en) | 2019-05-13 | 2025-12-18 | Novartis Ag | New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer |
| PH12022550976A1 (en) | 2019-10-24 | 2023-09-25 | Kinnate Biopharma Inc | Inhibitors of raf kinases |
| CN114746417B (zh) * | 2019-12-06 | 2023-12-08 | 齐鲁制药有限公司 | Pan-RAF激酶抑制剂的联芳基化合物 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| EP4326256A4 (en) | 2021-04-23 | 2025-03-19 | Pierre Fabre Medicament | Treating cancer with a RAF inhibition |
| KR20240000540A (ko) * | 2021-04-23 | 2024-01-02 | 킨네이트 바이오파마 인크. | (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태 |
| IL307793A (en) | 2021-05-12 | 2023-12-01 | Boehringer Ingelheim Int | Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
| DE3029376A1 (de) | 1980-07-31 | 1982-03-18 | Nepera Chemical Co. Inc., Harriman, N.Y. | Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen |
| EP0149884B1 (en) | 1983-09-09 | 1992-12-16 | Takeda Chemical Industries, Ltd. | 5-pyridyl-1,3-thiazole derivatives, their production and use |
| JP2722586B2 (ja) | 1989-01-13 | 1998-03-04 | 大正製薬株式会社 | インドリルイミダゾール誘導体 |
| JP2808460B2 (ja) | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| AU4618497A (en) | 1996-08-27 | 1998-03-19 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
| US6248771B1 (en) | 1997-03-05 | 2001-06-19 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| US6465493B1 (en) | 1999-04-09 | 2002-10-15 | Smithkline Beecham Corporation | Triarylimidazoles |
| KR100722344B1 (ko) | 1999-04-15 | 2007-05-29 | 브리스톨-마이어스스퀴브컴파니 | 환형 단백질 티로신 키나제 억제제 |
| JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
| US6310574B1 (en) | 1999-08-05 | 2001-10-30 | Vega Grieshaber Kg | Level transmitter |
| WO2001021598A1 (en) | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| CA2395564A1 (en) | 1999-11-22 | 2001-05-31 | Smithkline Beecham Plc | Novel compounds |
| PT1251848E (pt) | 2000-01-18 | 2004-10-29 | Vertex Pharma | Inibidores de girase e as sua utilizacoes |
| EP1251849A1 (en) | 2000-01-18 | 2002-10-30 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| ES2218391T3 (es) | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| CA2404384A1 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| MXPA02012314A (es) | 2000-06-12 | 2004-09-06 | Eisai Co Ltd | Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos. |
| WO2002042273A2 (en) | 2000-11-07 | 2002-05-30 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| JP4217480B2 (ja) | 2000-11-20 | 2009-02-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP2004517080A (ja) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| ES2274005T3 (es) | 2001-01-26 | 2007-05-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidores de malonyl-coa decarboxilasa usados como moduladores metabolicos. |
| WO2002062792A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| WO2002076960A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transition metal mediated process |
| JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| ES2336094T3 (es) | 2002-03-29 | 2010-04-08 | Novartis Vaccines And Diagnostics, Inc. | Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf. |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| EP1542990B1 (en) | 2002-09-18 | 2009-06-17 | Pfizer Products Inc. | Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| AU2003256003A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| EP1673343A4 (en) | 2003-10-08 | 2008-09-10 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
| ES2327418T3 (es) | 2003-10-16 | 2009-10-29 | Novartis Vaccines And Diagnostics, Inc. | Benzazoles sustituidos y uso de los mismos como inhibidores de la quinasa raf. |
| EP1692113B1 (en) | 2003-11-14 | 2017-09-27 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| RU2367661C2 (ru) | 2004-03-05 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные тиазола |
| KR100749566B1 (ko) | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2006026306A1 (en) | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylimidazoles as tgf-beta inhibitors |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| WO2006044509A2 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| JP2007246520A (ja) | 2006-02-15 | 2007-09-27 | Takeda Yuichiro | Ｒａｇｅ阻害剤 |
| US8217037B2 (en) | 2006-04-07 | 2012-07-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| CN101842361B (zh) | 2007-06-27 | 2013-06-05 | 阿斯利康(瑞典)有限公司 | 吡嗪酮衍生物及其在治疗肺病中的用途 |
| AR067354A1 (es) * | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| NZ582349A (en) | 2007-06-29 | 2012-06-29 | Sunesis Pharmaceuticals Inc | Heterocyclic compounds useful as raf kinase inhibitors |
| CA2692379A1 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| WO2009007749A2 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| CA2695004C (en) | 2007-07-17 | 2016-01-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8293747B2 (en) | 2007-07-19 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| WO2009032667A1 (en) | 2007-08-29 | 2009-03-12 | Smithkline Beecham Corporation | Thiazole and oxazole kinase inhibitors |
| UY31322A1 (es) | 2007-09-05 | 2009-04-30 | Amidas heterocíclicas y sus métodos de uso-975 | |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| AU2009227013B2 (en) | 2008-03-21 | 2013-01-10 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| MX2010013559A (es) | 2008-06-11 | 2011-05-19 | Irm Llc | Compuestos y composiciones utiles para el tratamiento de malaria. |
| EP2324008B1 (en) | 2008-07-24 | 2012-05-09 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| SG172248A1 (en) | 2008-12-19 | 2011-07-28 | Vertex Pharma | Pyrazine derivatives useful as inhibitors of atr kinase |
| US20120040951A1 (en) * | 2008-12-30 | 2012-02-16 | Claudio Chuaqui | Heteroaryl compounds useful as raf kinase inhibitors |
| SG178561A1 (en) * | 2009-08-28 | 2012-03-29 | Array Biopharma Inc | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| CA2771563A1 (en) | 2009-09-04 | 2011-03-10 | Novartis Ag | Bipyridines useful for the treatment of proliferative diseases |
| WO2011059610A1 (en) | 2009-11-10 | 2011-05-19 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
| TWI523851B (zh) | 2009-12-28 | 2016-03-01 | Yakult Honsha Kk | 1,3,4-oxadiazole-2-carboxamide |
| US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
| KR20110123657A (ko) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| EA201201676A1 (ru) | 2010-06-25 | 2013-06-28 | Новартис Аг | Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы |
| CN101993415B (zh) | 2010-09-15 | 2013-08-14 | 北京韩美药品有限公司 | 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用 |
| TR201816421T4 (tr) | 2011-02-07 | 2018-11-21 | Plexxikon Inc | Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları. |
| EP2739143B1 (en) | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| AP2014007493A0 (en) | 2011-09-01 | 2014-03-31 | Irm Llc | Compounds and compositions as C-KIT kinase inhibitors |
| CN102993199A (zh) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
| US9175011B2 (en) | 2011-09-21 | 2015-11-03 | Cellzone Limited | Morpholino substituted urea or carbamate derivatives as MTOR inhibitors |
| US9399638B2 (en) | 2012-05-02 | 2016-07-26 | Lupin Limited | Substituted pyridine compounds as CRAC modulators |
| JP6078640B2 (ja) | 2012-05-15 | 2017-02-08 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| TW201414704A (zh) | 2012-07-02 | 2014-04-16 | Biogen Idec Inc | 作爲ＲＯＲ－γ受體之反向促效劑之含聯芳化合物 |
| US9586948B2 (en) | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2015
- 2015-09-10 UY UY0001036294A patent/UY36294A/es not_active Application Discontinuation
- 2015-09-11 BR BR112017004741A patent/BR112017004741A2/pt not_active IP Right Cessation
- 2015-09-11 AU AU2015313782A patent/AU2015313782B2/en not_active Ceased
- 2015-09-11 US US14/851,249 patent/US9573969B2/en active Active
- 2015-09-11 KR KR1020177009468A patent/KR20170053686A/ko not_active Withdrawn
- 2015-09-11 JP JP2017513759A patent/JP6678655B2/ja active Active
- 2015-09-11 CU CUP2017000026A patent/CU20170026A7/es unknown
- 2015-09-11 CN CN201580061323.4A patent/CN107108671B/zh active Active
- 2015-09-11 CR CR20170092A patent/CR20170092A/es unknown
- 2015-09-11 ES ES15766660T patent/ES2729243T3/es active Active
- 2015-09-11 SG SG11201701734QA patent/SG11201701734QA/en unknown
- 2015-09-11 EA EA201790599A patent/EA031061B1/ru not_active IP Right Cessation
- 2015-09-11 AP AP2017009830A patent/AP2017009830A0/en unknown
- 2015-09-11 PE PE2017000445A patent/PE20171338A1/es not_active Application Discontinuation
- 2015-09-11 AR ARP150102898A patent/AR101815A1/es unknown
- 2015-09-11 WO PCT/IB2015/056986 patent/WO2016038581A1/en not_active Ceased
- 2015-09-11 TN TN2017000075A patent/TN2017000075A1/en unknown
- 2015-09-11 TW TW104130161A patent/TWI603977B/zh not_active IP Right Cessation
- 2015-09-11 EP EP15766660.3A patent/EP3191472B1/en active Active
- 2015-09-11 CA CA2960971A patent/CA2960971A1/en not_active Abandoned
- 2015-09-11 MX MX2017003233A patent/MX2017003233A/es unknown
-
2017
- 2017-01-04 US US15/397,787 patent/US9809610B2/en active Active
- 2017-03-05 IL IL250950A patent/IL250950A0/en unknown
- 2017-03-06 PH PH12017500416A patent/PH12017500416A1/en unknown
- 2017-03-07 ZA ZA2017/01633A patent/ZA201701633B/en unknown
- 2017-03-07 CL CL2017000541A patent/CL2017000541A1/es unknown
- 2017-03-08 CO CONC2017/0002292A patent/CO2017002292A2/es unknown
- 2017-03-09 DO DO2017000066A patent/DOP2017000066A/es unknown
- 2017-03-10 NI NI201700029A patent/NI201700029A/es unknown
- 2017-03-10 SV SV2017005405A patent/SV2017005405A/es unknown
- 2017-04-07 EC ECIEPI201721897A patent/ECSP17021897A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171338A1 (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| PE20161438A1 (es) | Inhibidores de desmetilasa 1 especifica a lisina | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| PE20170004A1 (es) | Inhibidores de biaril cinasa | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| MX374513B (es) | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. | |
| PE20191137A1 (es) | Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1) | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| PE20160875A1 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| EA201492092A1 (ru) | Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1 | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MX371312B (es) | Pirazolil-ureas como inhibidores de quinasas. | |
| UA113470C2 (xx) | Піримідинові та піридинові сполуки та їх застосування | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| JP2017528475A5 (OSRAM) | ||
| PH12013501754A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| NZ711376A (en) | Heteroaryl compounds and uses thereof | |
| EA201301302A1 (ru) | Производные пиридина и пиразина | |
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |